NPY L7P polymorphism and metabolic diseases.

NPY L7P polymorphism and metabolic diseases. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

NPY L7P polymorphism and metabolic diseases. Abstract Text:

Neuropeptide Y (NPY) is an abundant and widespread peptide in mammalian nervous system, both in the central and peripheral nervous systems. NPY is a multifunctional neurotransmitter with multiple modulator effects in the regulation of physiological functions and responses in the body. NPY is a potent orexigenic peptide, which has effects on energy balance at the level of energy intake, expenditure, and partition. There are many association studies between the NPY gene variants and cardiovascular and metabolic disease. Most of them are done by using p.L7P substitution as a marker. At the moment it seems that the p.L7P substitution of preproNPY protein causes altered NPY secretion, which leads to haemodynamic disturbances caused by sympathetic hyperactivity and to various effects caused by altered local signalling by NPY. SNP association studies using p.L7P polymorphism suggest that this functional substitution may be a strong independent risk factor for various metabolic and cardiovascular diseases.

NPY L7P polymorphism and metabolic diseases. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

NPY L7P polymorphism and metabolic diseases. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Regulatory peptides

VOLUME: 149

Page Numbers: 51-5

Journal Abbreviation: Regul. Pept.

ISSN: 0167-0115

DAY: 3

MONTH: 04

YEAR: 2008

NPY L7P polymorphism and metabolic diseases. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8100479

NPY L7P polymorphism and metabolic diseases. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: NPY L7P polymorphism and metabolic diseases. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for NPY L7P polymorphism and metabolic diseases.

AFFILIATION: University of Turku, Department of Pharmacology, Drug Development and Therapeutics, FI-20014 Turun yliopisto, Finland.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Regul Pept

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

NPY L7P polymorphism and metabolic diseases Related Publications

• A transthoracic Doppler echocardiography study of C-reactive protein and coronary microcirculation in children after open heart surgery.
• Acute decrease of coronary flow after indomethacin delivery in newborn lambs.
• Analysis of atrioventricular plane movements by Doppler tissue imaging and M-mode in children with atrial septal defects before and after surgical and device closure.
• Atherosclerosis precursors in Finnish children and adolescents. XIV. Zinc and copper concentrations in deciduous teeth.
• Coil embolization of a neonatal pulmonary arteriovenous malformation.
• Coronary artery changes in newborn babies. A histological and electron microscopical study.
• Coronary blood flow in healthy neonates: effects of left ventricular function and mass.
• Education of medical personnel working in northern regions.
• Extrinsic and intrinsic factors relating to intimal thickening in children.
• Is increased intima-media thickness associated with preatherosclerotic changes in intrauterine growth restricted newborns?- Reply.
• Kinetic energy operators in linearized internal coordinates.
• Myocardial damage in children and its relation to coronary artery lesions.
• NPY L7P polymorphism and metabolic diseases.
• On abortive ova; on the cytology of fertilized ova in the white mouse.
• SICKNESS INSURANCE IN FINLAND.
• Signal-averaged electrocardiography in normal newborn infants.
• Studies on the excretion of urinary pregnanediol after steroid anesthesia (hydroxydione).
• THE ORGANIZATION OF MEDICAL CARE IN FINLAND.
• The Finnish hospital system today.
• The medical profession in Finland.
• [Recent problems in medical service.]
• [The World Health Organization, or WHO.]
• [The duties of the communal health officers today.]
• [The need for hospital beds and the factors affecting it, including measures to be taken to relieve the excess of patients.]